Newron Pharmaceuticals Presents H1 2024 Results and Business Update

Newron Pharmaceuticals S.p.A. reported its H1 2024 financial results and provided an update on its operational activities. The biopharmaceutical company, focused on therapies for central and peripheral nervous system diseases, showcased significant progress in clinical trials for its novel drug, Evenamide.

The key highlight was the positive outcome from studies 014/015, which demonstrated Evenamide's efficacy as an add-on therapy in treatment-resistant schizophrenia (TRS). More than 70% of patients experienced a significant reduction in disease severity, and 25% achieved remission. Furthermore, study 008A confirmed the drug's safety and effectiveness in chronic schizophrenia patients.

In the corporate sector, Newron secured a €15 million agreement for new share issuance and extended its EIB financing arrangement, highlighting strong investor confidence. Key executives also increased their holdings in the company, underscoring their commitment to its future.

Looking forward, Newron aims to initiate a pivotal Phase III trial for Evenamide in H1 2025 and anticipates closing a value-creating transaction around the drug, enhancing shareholder value and advancing clinical development.